Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) rose 1.3% on Friday . The company traded as high as $7.20 and last traded at $7.11, with a volume of 427,881 shares changing hands. The stock had previously closed at $7.02.

RPTP has been the subject of a number of recent research reports. Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a report on Friday, May 6th. Cowen and Company restated a “buy” rating and issued a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a report on Friday, August 19th. Zacks Investment Research upgraded Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a report on Thursday, August 11th. Citigroup Inc. cut shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and upped their price target for the company from $6.00 to $8.00 in a research report on Monday, August 8th. Finally, FBR & Co reaffirmed a “hold” rating and set a $10.00 price target on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.79.

The company’s market cap is $620.17 million. The stock has a 50-day moving average price of $6.41 and a 200-day moving average price of $5.20.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $32.05 million for the quarter, compared to the consensus estimate of $28.52 million. The business’s revenue was up 37.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.17) earnings per share. Equities analysts forecast that Raptor Pharmaceutical Corp. will post ($0.91) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Schwab Charles Investment Management Inc. raised its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 3.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 292,620 shares of the company’s stock after buying an additional 9,354 shares during the period. Schwab Charles Investment Management Inc. owned 0.34% of Raptor Pharmaceutical Corp. worth $1,522,000 as of its most recent filing with the SEC.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.